TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33244706

Group type: EXPERIMENTAL
Intervention: GuttaCore
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Thermafil
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Continuous wave condensation
Number of subjects: 212

Group type: COMPARATOR
Intervention: Single cone with AH plus
Number of subjects: 212

Group type: COMPARATOR
Intervention: Single cone with BioRoot RCS
Number of subjects: 212
Study: 32047245

Group type: EXPERIMENTAL
Intervention: 5 g TestimTM gel (containing 50 mg testosterone)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 96
Study: 35041624

Group type: EXPERIMENTAL
Intervention: Fasting single methane measurement (SMM) ≥10 ppm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antibiotics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SMM
Number of subjects: 0
Study: 32892305

Group type: EXPERIMENTAL
Intervention: Preferred music therapy (PMT) which included educational counseling (EC) plus 15, 30-min preferred music sessions (PMS)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Educational counseling (EC) which included a 1-h individualized instruction
Number of subjects: 60
Study: 35771264

Group type: EXPERIMENTAL
Intervention: Afatinib
Number of subjects: 36

Group type: COMPARATOR
Intervention: Giotrif®
Number of subjects: 36
Study: 34987115

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Active Control (physical exercise and health education)
Number of subjects: 57
Study: 36067728

Group type: EXPERIMENTAL
Intervention: In-person counseling
Number of subjects: 961

Group type: EXPERIMENTAL
Intervention: Computer-generated individualized feedback letters
Number of subjects: 961

Group type: COMPARATOR
Intervention: Assessment only
Number of subjects: 961
Study: 32705913

Group type: EXPERIMENTAL
Intervention: Mobile predictive intervention used by Service Coordinators (SCs)
Number of subjects: 420

Group type: COMPARATOR
Intervention: Control group (no mobile predictive intervention)
Number of subjects: 420
Study: 32725584

Group type: EXPERIMENTAL
Intervention: Mirabegron 25 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mirabegron 50 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mirabegron (both doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mirabegron and Placebo
Number of subjects: 0
Study: 36206331

Group type: EXPERIMENTAL
Intervention: Randomization to foster care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 34288808

Group type: EXPERIMENTAL
Intervention: Levothyroxine treatment
Number of subjects: 165

Group type: COMPARATOR
Intervention: Control (Euthyroid women)
Number of subjects: 165
Study: 32733703

Group type: EXPERIMENTAL
Intervention: TBFP1 (based on circumferences)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: TBFP2 (based on skinfold thickness)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: TBFP4 (based on highly significant circumferences and skinfold thickness)
Number of subjects: 350
Study: 36069798

Group type: EXPERIMENTAL
Intervention: Blended Cognitive Behavioral Therapy (B‐CBT) - 6 sessions of face-to-face CBT alternated with 6-8 web-based CBT self-help modules.
Number of subjects: 76

Group type: COMPARATOR
Intervention: Face-to-Face Cognitive Behavioral Therapy (FtF‐CBT) - 12 sessions of traditional face-to-face CBT.
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Blended Cognitive Behavioral Therapy (B‐CBT)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Face-to-Face Cognitive Behavioral Therapy (FtF‐CBT)
Number of subjects: 76
Study: 34111592

Group type: EXPERIMENTAL
Intervention: Uva ursi (UU) 105 mg 3 × 2 tablets for 5 days
Number of subjects: 398

Group type: COMPARATOR
Intervention: Fosfomycin 3-g single dose
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Uva ursi (UU)
Number of subjects: 398

Group type: COMPARATOR
Intervention: Fosfomycin
Number of subjects: 398
Study: 35301883

Group type: EXPERIMENTAL
Intervention: AD‐MSCs
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 13
Study: 32107269

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 50
Study: 33221606

Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy (IPT) group treatment for perinatal depression, 12 sessions
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 49
Study: 32328709

Group type: EXPERIMENTAL
Intervention: Drospirenone-only pill 4 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Desogestrel 0.075 mg
Number of subjects: 0
Study: 35210118

Group type: EXPERIMENTAL
Intervention: Intradermal fractional third dose of AZD1222 vaccine (20% of standard dose)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Intradermal fractional third dose of AZD1222 vaccine (40% of standard dose)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Standard intramuscular third dose of AZD1222 vaccine
Number of subjects: 125
Study: 34735395

Group type: EXPERIMENTAL
Intervention: 35% N2O with i.v. remifentanil infusion at 0.1 μg kg‐1 min‐1
Number of subjects: 21

Group type: COMPARATOR
Intervention: 50% N2O with i.v. remifentanil infusion at 0.1 μg kg‐1 min‐1 (gas active control)
Number of subjects: 21

Group type: COMPARATOR
Intervention: i.v. remifentanil infusion at 0.1 μg kg‐1 min‐1
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 35% N2O
Number of subjects: 21
Study: 33788484

Group type: EXPERIMENTAL
Intervention: Acupoint electrical stimulation therapy at Huantiao (GB 30), Futu (ST 32), Zusanli (ST 36), Xuanzhong (GB 39), and Taichong (LR 3), 2 times daily for 7 days.
Number of subjects: 58

Group type: COMPARATOR
Intervention: Routine basic treatment (Control group).
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Acupoint electrical stimulation therapy.
Number of subjects: 58
Study: 32947572

Group type: EXPERIMENTAL
Intervention: Light-load ballistic resistance training (LL: 6 × 12 × 40% 1RM)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Heavy-load ballistic resistance training (HL: 6 × 6 × 80% 1RM)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Light-load ballistic resistance training (LL)
Number of subjects: 15
Study: 34534292

Group type: COMPARATOR
Intervention: TS‐161 (15-400 mg single dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: TS‐161 (50-150 mg multiple doses over 10 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: TS‐161 (100 mg single dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: TS‐161
Number of subjects: 0
Study: 32771034

Group type: EXPERIMENTAL
Intervention: Nigella sativa oil (MARNYS® Cuminmar) 500 mg softgel capsules, one capsule orally twice daily for 10 days plus standard of care treatment (antipyretic, antitussive)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard of care treatment
Number of subjects: 200
Study: 36427258

Group type: EXPERIMENTAL
Intervention: Verum electroacupuncture stimulation (EAS) at scalp acupoints Shenting (GV24) and Touwei (ST8) during fMRI.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham acupuncture stimulation at acupoints Shenting (GV24) and Touwei (ST8) without EAS during fMRI.
Number of subjects: 60
Study: 33958862

Group type: EXPERIMENTAL
Intervention: Lung Function Questionnaire (LFQ) followed by pocket spirometry
Number of subjects: 3256
Study: 33635779

Group type: EXPERIMENTAL
Intervention: Choice of medication reminder modality (text, email, phone)
Number of subjects: 7522

Group type: COMPARATOR
Intervention: Usual care (no choice of reminder modality)
Number of subjects: 7522
Study: 35452419

Group type: EXPERIMENTAL
Intervention: Bevacizumab (BVZ) plus XELOX chemotherapy with mindfulness-based stress reduction (MBSR) intervention
Number of subjects: 88

Group type: COMPARATOR
Intervention: XELOX chemotherapy with conventional care
Number of subjects: 88
Study: 32949505

Group type: EXPERIMENTAL
Intervention: RIMA vascular device occlusion (verum group)
Number of subjects: 100

Group type: COMPARATOR
Intervention: RIMA sham procedure (placebo group)
Number of subjects: 100
Study: 34739648

Group type: EXPERIMENTAL
Intervention: Remote Ischaemic Conditioning (RIC) - four 5-min cycles of inflation (20 mmHg above systolic blood pressure) and deflation of an automated blood pressure cuff placed on the upper arm, applied daily for 2 days.
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Sham control - similar protocol but with low-pressure inflation of 20 mmHg and deflation, applied daily for 2 days.
Number of subjects: 1200
Study: 33955942

Group type: EXPERIMENTAL
Intervention: Yogic pranayama and diaphragmatic breathing exercises (daily for 6 months)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 90
Study: 32943015

Group type: EXPERIMENTAL
Intervention: Three-monthly multimodal vascular risk factor intervention jointly delivered by the trial team and General Practitioner (GP)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Usual care from the GP (Control)
Number of subjects: 73
Study: 35850666

Group type: EXPERIMENTAL
Intervention: Placental cord drainage
Number of subjects: 400

Group type: COMPARATOR
Intervention: No placenta drainage (Control)
Number of subjects: 400
Study: 33893865

Group type: EXPERIMENTAL
Intervention: Er:YAG laser treatment with meibomian gland expression (MGX)
Number of subjects: 64

Group type: COMPARATOR
Intervention: MGX-alone treatment
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Er:YAG laser treatment with MGX
Number of subjects: 64
Study: 32664084

Group type: EXPERIMENTAL
Intervention: HT083
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 33755978

Group type: EXPERIMENTAL
Intervention: Colostrum combined with sodium bicarbonate nursing (experimental group)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Colostrum (control group I)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sodium bicarbonate (control group II)
Number of subjects: 120
Study: 35084893

Group type: EXPERIMENTAL
Intervention: Family-focused therapy (FFT) for 4 months
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Family-focused therapy (FFT)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Enhanced care (EC)
Number of subjects: 119
Study: 32017856

Group type: EXPERIMENTAL
Intervention: Dextrose prolotherapy + Short Wave Diathermy (SWD)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Dextrose prolotherapy with sham SWD
Number of subjects: 63
Study: 34158133

Group type: EXPERIMENTAL
Intervention: Cryoprotectant with pentoxifylline
Number of subjects: 68

Group type: COMPARATOR
Intervention: Cryoprotectant without pentoxifylline
Number of subjects: 68
Study: 34530894

Group type: EXPERIMENTAL
Intervention: Group-based Problem Management Plus (group PM+) with antidepressant therapy (ADT)
Number of subjects: 420

Group type: COMPARATOR
Intervention: Usual care (baseline chronic care services)
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness model
Number of subjects: 420
Study: 35690556

Group type: EXPERIMENTAL
Intervention: Sofosbuvir/ledipasvir
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Number of subjects: 190

Group type: COMPARATOR
Intervention: Standard Care Treatment (SCT)
Number of subjects: 190
Study: 34396571

Group type: EXPERIMENTAL
Intervention: 900 µg εPA‐44
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: 600 µg εPA‐44
Number of subjects: 360

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 360
Study: 34229888

Group type: EXPERIMENTAL
Intervention: MVA/HIV62B alone (T1; n = 4)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: MVA/HIV62B and AIDSVAX B/E (T2; n = 4)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: MVA/HIV62B alone (T3; n = 6)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: MVA/HIV62B and AIDSVAX B/E (T4; n = 6)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: AIDSVAX B/E alone (T5; n = 7)
Number of subjects: 27
Study: 36380348

Group type: EXPERIMENTAL
Intervention: Anapana meditation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Body scan meditation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metta meditation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All interventions (Anapana, Body Scan, Metta)
Number of subjects: 0
Study: 33835256

Group type: EXPERIMENTAL
Intervention: Fluoride Varnish (DuraphatTM, 5% NaF)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Xylitol Varnish (20% xylitol)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo Varnish (no F/Xylitol)
Number of subjects: 55
Study: 34653953

Group type: EXPERIMENTAL
Intervention: 0.02% HOCl nasal spray three times a day for two months
Number of subjects: 78

Group type: COMPARATOR
Intervention: Normal saline (NS) nasal irrigation
Number of subjects: 78
Study: 33403697

Group type: EXPERIMENTAL
Intervention: Intradermal adalimumab (40 mg, 0.4 mL)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Subcutaneous adalimumab (40 mg)
Number of subjects: 24
Study: 33429151

Group type: EXPERIMENTAL
Intervention: Cognitive Remediation (CR)
Number of subjects: 1084
Study: 34621450

Group type: EXPERIMENTAL
Intervention: Home Medication Review by Community Pharmacists (HMR‐CP)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 166
Study: 35652296

Group type: EXPERIMENTAL
Intervention: DHA-rich algae oil
Number of subjects: 528

Group type: EXPERIMENTAL
Intervention: DHA-rich algae oil (for neonates born <27 weeks' GA)
Number of subjects: 528

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 528
Study: 33434700

Group type: EXPERIMENTAL
Intervention: Parenting intervention delivered through health services in Jamaica from age 3 to 18 months.
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Initial trial benefits at 18 months (effect size 0.34–0.38 standard deviation).
Number of subjects: 262
Study: 32387542

Group type: EXPERIMENTAL
Intervention: Tetanus toxoid (TT) vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Purified protein derivative of Mycobacterium tuberculosis (PPD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sm infection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nematode infection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Urban-rural comparison
Number of subjects: 0
Study: 35091050

Group type: EXPERIMENTAL
Intervention: Quetiapine (400-600 mg)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Lithium (1.0-1.2 mEq/L)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 71
Study: 32224716

Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IPC) using 220 mm Hg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Cuff control protocol with 20 mm Hg (CUFF)
Number of subjects: 16

Group type: COMPARATOR
Intervention: No IPC (control) (CON)
Number of subjects: 16
Study: 35719216

Group type: EXPERIMENTAL
Intervention: Topical lidocaine-prilocaine (EMLA®)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Standard of care (control)
Number of subjects: 72
Study: 35373776

Group type: EXPERIMENTAL
Intervention: Web-based psychosocial therapy program via smartphone for 6 weeks
Number of subjects: 209

Group type: COMPARATOR
Intervention: Control group with access to self-help audiovisual material
Number of subjects: 209
Study: 33950184

Group type: EXPERIMENTAL
Intervention: Home-delivered pill packs in prepackaged blisters
Number of subjects: 80

Group type: COMPARATOR
Intervention: Routine pharmacy prescriptions (Control)
Number of subjects: 80
Study: 32840201

Group type: EXPERIMENTAL
Intervention: Silver-impregnated ceramic water filter
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Silver-impregnated ceramic tablet
Number of subjects: 404

Group type: COMPARATOR
Intervention: Safe-storage water container
Number of subjects: 404

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 404
Study: 35048793

Group type: EXPERIMENTAL
Intervention: Patient-reported outcome-based telehealth follow-up by a rheumatologist (PRO-TR)
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Patient-reported outcome-based telehealth follow-up by a nurse (PRO-TN)
Number of subjects: 294

Group type: COMPARATOR
Intervention: Conventional outpatient follow-up (control)
Number of subjects: 294
Study: 33582566

Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Tobacco smoking
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Alcohol intake
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Time since diagnosis
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Disease severity
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Physical activity/exercise
Number of subjects: 417
Study: 35135006

Group type: EXPERIMENTAL
Intervention: D-allulose
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Erythritol
Number of subjects: 18

Group type: COMPARATOR
Intervention: Lactisole
Number of subjects: 18

Group type: COMPARATOR
Intervention: Tap water
Number of subjects: 18
Study: 34930206

Group type: EXPERIMENTAL
Intervention: Educational intervention based on Watson's Theory of Human Caring
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 101
Study: 35717048

Group type: EXPERIMENTAL
Intervention: Risk-adapted intraoperative radiation therapy (IORT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: External beam radiation therapy (control)
Number of subjects: 0
Study: 33239101

Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis
Number of subjects: 506

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 506
Study: 35594017

Group type: EXPERIMENTAL
Intervention: HLX11
Number of subjects: 160
Study: 34256114

Group type: EXPERIMENTAL
Intervention: Resistance training in hypoxia (RTH)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Resistance training in normoxia (RTN)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 54
Study: 32653666

Group type: EXPERIMENTAL
Intervention: Standardized patient
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-fidelity simulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Partial task trainer
Number of subjects: 0
Study: 34942106

Group type: EXPERIMENTAL
Intervention: Community Health Worker (CHW) intervention
Number of subjects: 42

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 42
Study: 32348638

Group type: EXPERIMENTAL
Intervention: Inhaled steroids (IS) before weaning
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Inhaled steroids (IS) after weaning
Number of subjects: 174

Group type: COMPARATOR
Intervention: No inhaled steroids (IS)
Number of subjects: 174

Group type: COMPARATOR
Intervention: NICU clinics
Number of subjects: 174

Group type: COMPARATOR
Intervention: Pulmonary clinics
Number of subjects: 174
Study: 34910554

Group type: EXPERIMENTAL
Intervention: Genomically directed therapy (arm A)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Treatment of physician choice (TPC) (arm B)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Circulating tumor DNA status
Number of subjects: 193
Study: 32060099

Group type: EXPERIMENTAL
Intervention: High-dose icotinib (250 mg, thrice daily; L858R-HD)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Routine-dose icotinib (125 mg, thrice daily; L858R-RD)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Routine-dose icotinib (125 mg, thrice daily; 19-Del-RD)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: High-dose icotinib (L858R-HD)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Routine-dose icotinib (L858R-RD)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Routine-dose icotinib (19-Del-RD)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 253
Study: 35113435

Group type: EXPERIMENTAL
Intervention: Aerobic training three times per week for 12 weeks along with a balanced diet
Number of subjects: 40

Group type: COMPARATOR
Intervention: Balanced diet only
Number of subjects: 40
Study: 34489267

Group type: EXPERIMENTAL
Intervention: Usual care supplemented with vertebroplasty
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 100
Study: 32997237

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Number of subjects: 2075
Study: 34971579

Group type: COMPARATOR
Intervention: Low-dose hydroxyurea (10 mg/kg per day)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Moderate-dose hydroxyurea (20 mg/kg per day)
Number of subjects: 220
Study: 33950156

Group type: EXPERIMENTAL
Intervention: Sustained care (SusC) smoking cessation intervention
Number of subjects: 342

Group type: COMPARATOR
Intervention: Usual care (UC) smoking cessation intervention
Number of subjects: 342
Study: 32892320

Group type: EXPERIMENTAL
Intervention: Spirulina (6 g/day for 7 days)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 36852512

Group type: EXPERIMENTAL
Intervention: Immediate removal of urinary catheter
Number of subjects: 693

Group type: COMPARATOR
Intervention: Delayed removal of urinary catheter
Number of subjects: 693
Study: 32745555

Group type: EXPERIMENTAL
Intervention: Rituximab with azathioprine or mycophenolate mofetil
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Retreatment with immunosuppressive therapy
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Immunosuppressive therapy
Number of subjects: 39
Study: 32810146

Group type: EXPERIMENTAL
Intervention: Couples' UBL
Number of subjects: 6770

Group type: EXPERIMENTAL
Intervention: Women's UBL
Number of subjects: 6770

Group type: EXPERIMENTAL
Intervention: Men's UBL
Number of subjects: 6770

Group type: COMPARATOR
Intervention: Control
Number of subjects: 6770
Study: 36250608

Group type: EXPERIMENTAL
Intervention: Music enrichment program (Music Together®)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Active play date control
Number of subjects: 90
Study: 33471029

Group type: EXPERIMENTAL
Intervention: Systematic echocardiographic screening followed by secondary antibiotic prophylaxis
Number of subjects: 3973

Group type: COMPARATOR
Intervention: No echocardiographic screening
Number of subjects: 3973
Study: 34688520

Group type: EXPERIMENTAL
Intervention: Nanocrystalline silver dressings
Number of subjects: 100

Group type: COMPARATOR
Intervention: 1% silver sulfadiazine dressings
Number of subjects: 100